经肝动脉药盒持续灌注氟脲苷与地塞米松治疗化疗抵抗的结直.pdfVIP

中华临床医师杂志( 电子版)2014 年1 月第8 卷第2 期 Chin J Clinicians(Electronic Edition),January 15,2014,Vol.8,No.2 ·211 · ·临床论著· 经肝动脉药盒持续灌注氟脲苷与地塞米松 治疗化疗抵抗的结直肠癌肝转移的 疗效与安全性分析 江露 石亮荣 赵洁敏 李争光 羌伟光 吴骏 季枚 吴昌平 【摘要】 目的 探讨经肝动脉药盒灌注氟脲苷与地塞米松治疗化疗抵抗的结直肠癌肝转移的疗 效及安全性。方法 对23 例经过至少二线化疗失败的结直肠癌肝转移患者采用介入放射方法植入肝 动脉药盒，术后第2 天开始经药盒灌注氟脲苷与地塞米松，对其治疗疗效、毒副反应及生存状态进 行回顾性分析。结果 23 例患者的肝内疾病控制率为69.6%，其中部分缓解10 例（43.5% ），稳定 6 例（26.1% ）；4 例患者转化为可手术切除，转化率为 17.4%。中位肝内无进展生存时间为（9.0 ±1.8） 月，中位总生存时间为（14.0 ±1.8）月。结论 经肝动脉药盒灌注氟脲苷与地塞米松可作为化疗抵 抗的结直肠癌肝转移的补救治疗，并可能使部分患者转化为可手术切除，从而获得长期生存的机会。 【关键词】 结直肠肿瘤； 肿瘤转移； 肝转移瘤； 肝动脉灌注 Efficacy and safety of hepatic arterial infusion fluorouracil plus dexamethasone in patients with chemotherapy-refractory liver metastases from colorectal cancer Jiang Lu, Shi Liangrong, Zhao Jiemin, Li Zhengguang, Qiang Weiguang, Wu Jun, Ji Mei, Wu Changping. Department of Oncology, the Third Hospital of Soochow University, Changzhou 213003, China Corresponding author: Shi Liangrong, Email: shiliangr@126.com 【Abstract 】 Objective To evaluate the efficacy and safety of the hepatic arterial infusion (HAI) fluorouracil (FUDR) plus dexamethasone for patients with chemotherapy-refractory colorectal cancer liver metastases(CRCLM). Methods HAI catheter systems were implanted by an innovative radiological method in 23 CRCLM patients who had progressive diseases after at least second-line systemic chemotherapy. HAI FUDR and dexamethasone were delivered in the next day after catheter implantation. The short-term effects, adverse events related to treatments and survival data were analyzed retrospectively. Results The hepatic disease control rate was 69.6%, including partial responses 43.5% and stable disease 26.1%. The median hepatic progression-free survival and overall survival was (9.0 ±1.8) and (14.0±1.8) months respec